VetDC Completes $1.5M Financing to Advance Agent for Canine Lymphoma
VetDC, a Fort Collins, Colorado-based veterinary biotechnology startup, has completed a $1.5m financing.
The company intends to use the funds to advance its novel targeted agent VDC-1101 towards veterinary approval in canine lymphoma.
Led by Steven Roy, President & CEO, VetDC is a Colorado State University startup focused on in-licensing, developing and commercializing novel biotechnologies to address serious unmet medical needs in companion animals. In 2011, the company secured seed funding from the Colorado Institute for Drug, Device and Diagnostic Development (CID4).